TGA + Australia's CMO Warn of Five Peptide Risks

Peptides are short chains of amino acids that act as the body's signalling molecules. In Australia, they have been under heightened scrutiny since 19 June 2026. The Therapeutic Goods Administration (TGA) and Australia's Chief Medical Officer have jointly warned of unapproved products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 - substances that are often marketed online as miracle remedies for faster healing, anti-aging, or muscle growth. Documented harms include liver damage, severe allergic reactions, and inflammation requiring hospital treatment.

What exactly do the authorities say?

The joint statement was published on 19 June 2026, signed by Dr Amanda Cuss (Acting Chief Medical Adviser, Health Products Regulation Group at the TGA) and Professor Michael Kidd AM (Australia's Chief Medical Officer). The core message: peptide products not listed in the Australian Register of Therapeutic Goods (ARTG) have not been evaluated for safety, quality, or effectiveness, and concrete harm reports have now been received.

Three categories of serious adverse events are explicitly listed:

• Liver damage (acute hepatotoxicity). The liver is being actively injured; blood tests show typical warning signs: certain liver enzymes rise sharply (raised transaminases), a yellow breakdown product called bilirubin accumulates, and blood clotting can be impaired (coagulopathy) because the liver can no longer produce clotting factors properly.
• Severe allergic reactions that required hospitalisation
• Inflammation and other health complications requiring medical attention

The TGA also notes that many of these products arrive via Australia's Personal Importation Scheme, a rule that allows individuals to order small quantities for personal use, exactly the loophole grey-market vendors rely on. Often the labelling is missing or inadequate; sometimes only codes or abbreviations appear where the active ingredient name should be. The agency's head, Prof Anthony Lawler, called the move a 'deliberate, risk-based response' to a fast-growing grey market, meaning an intentional, risk-driven reaction, a targeted intervention because authorities see the situation as serious enough to act.

How did the warning come about?

On the same day, Victoria's Chief Health Officer Dr Caroline McElnay issued a Health Alert for clinicians. The trigger: six cases of acute liver injury in Victoria since January 2026, all linked to products labelled as "retatrutide", "reta", "R-10", or "R-20". According to the CHO, the products were obtained via online shops, social circles, and social-media advertisements.

This is how I read the picture: the liver cases are the trigger, but the warning itself is intentionally broader. I had already covered the Australian liver-injury cluster. What is genuinely new is that the TGA now expands the affected-peptide list beyond retatrutide to five substances, including BPC-157 and GHK-Cu, two of the most heavily promoted 'research' peptides online.

Which warning signs should you know?

Health authorities urge anyone who has used unapproved peptides to seek medical help promptly if they experience any of the following:

• unusual tiredness
• abdominal pain, especially in the right upper area
• itchy skin
• dark urine or pale stools
• yellow eyes or skin (jaundice)
• easy bruising or unusual bleeding

General practitioners in Australia were also asked to actively ask about peptide use when patients present with abnormal liver-function tests, even if symptoms appear mild at first. A simple blood panel (liver enzymes such as transaminases, the pigment bilirubin, and a clotting measure called INR) tells you how stressed the liver actually is.

What does this mean for Europe and Germany?

Australian alerts are not legally binding in the EU, but they add to the evidence base that the problem is real and growing. In the EU, peptides like BPC-157, TB-500, or GHK-Cu are sold via grey-market online channels, typically labelled 'research chemicals', shipped without a prescription, and often without stating the actual active ingredient. The Peptipedia Vendor Radar logged a freshly verified online scam vendor on 20 June 2026 (two reports, about 300 EUR in claimed losses).

Worth keeping in mind: with the exception of retatrutide, for which Phase 2 data (results from intermediate-stage human trials that first test whether a drug actually works in patients) on weight loss exist, solid efficacy evidence from controlled human trials for the marketed indications is essentially absent for the other peptides named here. For BPC-157 in particular, Phase-1 safety trials in humans (the very first, small-scale tests in healthy people that check whether a substance is even safe to give) remain missing. The Peptipedia evidence round-up on BPC-157 and GHK-Cu covers this in detail. If you still consider using such substances, at least know the benefit-risk profile is essentially unknown.

Note: peptides are short chains of amino acids; therapeutic use in Germany and the EU is almost exclusively restricted to approved medicines or physician-prescribed formulations. This article is for public information and is not medical advice, a dosing recommendation, or a purchasing recommendation.